Form 8-K - Current report:
SEC Accession No. 0001140361-24-046028
Filing Date
2024-11-12
Accepted
2024-11-12 08:23:21
Documents
15
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20038443_8k.htm   iXBRL 8-K 29587
2 EXHIBIT 99.1 ef20038443_ex99-1.htm EX-99.1 191701
6 image0.jpg GRAPHIC 306401
  Complete submission text file 0001140361-24-046028.txt   796022

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ird-20241112.xsd EX-101.SCH 3976
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20241112_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20241112_pre.xml EX-101.PRE 16041
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20038443_8k_htm.xml XML 4237
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 241443696
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)